Repros rises 76% on Phase III Androxal data
This article was originally published in Scrip
Executive Summary
In possibly the most bizarre public biotech company conference call ever, Repros Therapeutics president and CEO Joseph Podolski told investors and analysts that based on the first set of Phase III data for the oral testosterone therapy Androxal, "I believe deep in my heart this drug is going to get approved."